Lactobacillus, Pediococcus, Or Leuconostoc Patents (Class 435/252.9)
-
Publication number: 20110020303Abstract: The invention relates to the use of probiotics in the manufacture of a composition for enhancing a metabolic profile in a subject. The probiotics are capable of preventing and treating diseases or disorders associated with an abnormal metabolic profile, especially a lipid profile by normalizing the profile. The probiotics are particularly effective in down-regulating levels of lysophosphatiydylcholines (LysoPCs) and ceramides.Type: ApplicationFiled: February 4, 2009Publication date: January 27, 2011Applicant: VALIO, LTD.Inventors: Kajsa Kajander, Riitta Korpela
-
Publication number: 20110020283Abstract: A pharmaceutical composition for the prophylaxis, suppression or elimination of allergic reactions in humans, includes probiotic, gram-positive bacteria, such as, for example, Lactobacillus and Bifidobacterium as the substantial active ingredient and, more particularly, as viable bacteria, inactivated bacteria or the genomic DNA of such bacteria, or as a combination thereof.Type: ApplicationFiled: February 22, 2007Publication date: January 27, 2011Inventor: Jürgen Schrezenmeir
-
Publication number: 20110020494Abstract: The present invention provides lactic acid bacterial cultures. In some particularly preferred embodiments, the present invention provides cultures comprising lactic acid bacteria, a dairy substrate (e.g., milk or cream), at least one formate source, and at least one purine source. In some further embodiments, the cultures comprise exogenous lactase enzyme. The present invention also provides cultures of cells comprising the culture medium and lactic acid bacteria. The present invention further provides starter compositions (i.e., starter cultures) for starting the culture. In some embodiments, the compositions of the present invention find use in the production of fermented milk products (e.g., yogurt, cheese and/or fermented milk beverages).Type: ApplicationFiled: October 30, 2007Publication date: January 27, 2011Inventor: Lars Petersen
-
Publication number: 20110014168Abstract: Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found.Type: ApplicationFiled: November 29, 2007Publication date: January 20, 2011Applicant: Meiji Dairies CorporationInventors: Hirosi Tsuboi, Noriko Kaneko, Akina Satou, Yoshinobu Tsuchiya
-
Publication number: 20110014166Abstract: The present invention relates to the novel Sporolactobacillus vineae SL153 strain (Accession No: KCTC 11493BP) having probiotic activity, precisely Sporolactobacillus vineae SL153 having antimicrobial activity against Vibrio genus pathogenic microorganisms and other pathogens. The Sporolactobacillus vineae SL153 strain of the present invention has excellent intestinal adherence and growth inhibitory effect on pathogenic microorganisms including Vibrio genus microorganisms, so that it can be effectively used as a composition for the prevention and treatment of disease caused by pathogenic microorganisms.Type: ApplicationFiled: July 17, 2009Publication date: January 20, 2011Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Young-Hyo CHANG, Min-Young Jung, In-Soon Park
-
Publication number: 20110008874Abstract: A stable, pellet-frozen lactic acid bacteria (LAB) culture comprises at least one additive compound in a commercial relevant package. The pellet-frozen culture has at least 50 g frozen material and a content of viable bacteria of at least 109 colony forming units per gram of frozen material. The individual pellets of the frozen culture do not stick together and remain as individual pellets, when stored at about ?46° C., for at least 7 to 14 days.Type: ApplicationFiled: July 15, 2010Publication date: January 13, 2011Inventors: Rikke STAVNSBJERG, Inge Knap, Hans Bisgaard-Frantzen, Borge Windel Kringelum
-
Publication number: 20110008875Abstract: The present invention provides a method of preparing frozen or lyophilized microbial cells which can inhibit damages or death of microbial cells and have high viabilities in freezing or lyophilizing process. A method of preparing frozen or lyophilized microbial cells having high viabilities, characterized by using a permeate which is obtained by filtering milk or whey with ultra-filtration (UF) membrane, as a protecting agent at the time of freezing or lyophilizing.Type: ApplicationFiled: February 3, 2009Publication date: January 13, 2011Applicant: SNOW BRAND MILK PRODUCTS CO., LTD.Inventors: Naoki Azuma, Masayuki Watanabe, Hiroshi Ueno, Toshimitsu Yoshioka
-
Publication number: 20110002901Abstract: It is an object of the present invention to provide a bacterial strain belonging to Lactobacillus brevis subspecies brevis, which has more potent antiallergic activity than the known lactic acid bacteria strains and produces ?-aminobutyric acid (GABA). It is another object of the present invention to provide beverages and foods containing cells of the aforementioned bacterial strain belonging to Lactobacillus brevis subspecies brevis, as well as antiallergic agents containing them as an active ingredient. The present invention provides a bacterial strain belonging to Lactobacillus brevis subspecies brevis, which: is capable of growing in effervescent alcoholic beverages, produces ?-aminobutyric acid (GABA), and has antiallergic activity.Type: ApplicationFiled: August 20, 2007Publication date: January 6, 2011Applicant: SAPPORO BREWERIES LIMITEDInventors: Syuichi Segawa, Yasukazu Nakakita, Yoshihiro Takata, Hisako Yasui
-
Publication number: 20110002902Abstract: The present invention provides an inhibitor for blood phosphorus level elevation comprising a lactic acid bacterium as an active ingredient. The inhibitor for blood phosphorus level elevation of the present invention is highly safe, is readily administerable, and can sufficiently inhibit a blood phosphorus level elevation.Type: ApplicationFiled: March 2, 2009Publication date: January 6, 2011Inventors: Masanori Asada, Tadashi Kanaya, Tetsuya Ogawa, Mikiko Shimada, Yumi Uehara
-
Patent number: 7862808Abstract: The present invention is directed to a novel method for preventing or treating respiratory infections and acute otitis media in infants. The method comprises the administration of a therapeutically effective amount of a Bifidobacteria strain and an adherence-promoting probiotic, such as LGG, to the infant.Type: GrantFiled: June 29, 2005Date of Patent: January 4, 2011Assignee: Mead Johnson Nutrition CompanyInventors: Erika Isolauri, Seppo Salminen
-
Patent number: 7862809Abstract: A lactic composition containing at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus casei and a mixture of Lactobacillus acidophilus and Lactobacillus casei, and a whole broth of the bacterial strain or the mixture of the bacterial strains, is useful for the prevention or treatment of disorders which are angiogenesis dependant. Both the lactic composition and its supernatant can be used for prevention or treatment of angiogenesis dependant disorders. The supernatant of the lactic composition exhibits antiangiogenic properties.Type: GrantFiled: November 15, 2004Date of Patent: January 4, 2011Assignee: Bio-K Plus International, Inc.Inventors: Richard Beliveau, Francois-Marie Luquet
-
Patent number: 7863033Abstract: There has been effort to develop a lactobacillus that would be useful as a probiotic, and to develop a lactobacillus which would colonize and proliferate in lesions of infection, eliminating the causal bacteria. This problem was resolved by developing a Lactobacillus casei species having the following key properties. (1) The species can be grown in the presence of any of one to four amino acids as a nitrogen source necessary for growth. (2) When a growth-promoting culture medium is inoculated with the species and Escherichia coli in the same count and subjected to anaerobic mixed culturing at 37° C., the final count of lactobacilli is 50% or more of the coliform count. (3) Upon cultivation in an appropriate culture medium, the final pH value is 4.0 or below, and the highest acidity is 1.5% or more. (4) The species is resistant to 5% bile salts. (5) The species produces an antibiotic.Type: GrantFiled: July 27, 2004Date of Patent: January 4, 2011Assignee: BHPH Company LimitedInventors: Tadayo Hata, Hitoshi Toshimori, Toshiyuki Maruoka
-
Patent number: 7858336Abstract: Processes to produce microorganisms that can be incorporated into a microbial-based product that results in high viable cell yields and shelf-stable products are disclosed. These microbial-based products are useful for inhibiting pathogenic growth and as a food additive. A preferred microorganism is the lactic acid producing bacteria, Lactobacillus amylovorus M35. In one embodiment, the process comprises inoculating a lactobacillus fermentation medium with M35 cells, harvesting the M35 cells at mid to late log phase, concentrating the M35 cells, and preserving the M35 cells at a concentration of at least 5×109 cfu/ml.Type: GrantFiled: June 24, 2010Date of Patent: December 28, 2010Assignee: MicroBios, Inc.Inventors: Matthew Ryan Garner, Joseph Flint
-
Publication number: 20100322964Abstract: The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.Type: ApplicationFiled: May 12, 2010Publication date: December 23, 2010Inventors: Véronique Dennin, Gregory John Leyer, Annick Mercenier, Sophie Nutten, Bruno Pot
-
Publication number: 20100316618Abstract: The present invention provides lactic acid bacteria which are suitable for use for dietary products and pharmaceuticals, and which can suppress the increase of blood uric acid level. Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2922, were found.Type: ApplicationFiled: November 27, 2008Publication date: December 16, 2010Applicant: MEIJI DAIRIES CORPORATIONInventors: Hiroshi Tsuboi, Noriko Kaneko, Akina Satou, Akinori Kume, katsunori Kimura
-
Publication number: 20100310718Abstract: Liquid microbial starter culture that retains its initial metabolic activity during storage for extended periods of time. Such liquid starter cultures are useful in the manufacturing of food and feed products. Starter cultures of the invention include culture of lactic acid bacteria, e.g. Lactococcus species.Type: ApplicationFiled: April 29, 2010Publication date: December 9, 2010Inventors: Boerge Kringelum, Lene Kragelund
-
Patent number: 7846711Abstract: The invention concerns new isolated Lactobacillus cells, which are capable to aggregate Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.Type: GrantFiled: December 22, 2006Date of Patent: December 7, 2010Assignee: Organobalance GmbHInventors: Mewes Boettner, Eckhard Budde, Christine Lang, Martin Ryser, Markus Veen
-
Publication number: 20100303777Abstract: Delivery of binding molecules, such as antibodies, antibody fragments, single antibody variable domains, soluble receptors, ligands and dominant negative variants, to induce an immunomodulation in a patient is disclosed. More specifically, a medicament which includes micro-organisms which produce the binding molecules is described for the treatment of immune mediated diseases.Type: ApplicationFiled: December 12, 2007Publication date: December 2, 2010Applicant: ActoGeniX N.V.Inventors: An De Creus, Pieter Rottiers
-
Patent number: 7842495Abstract: The invention provides lactic acid bacteria selected from the group consisting of lactobacillus ONRIC b0239 (FERM BP-10064) and lactobacillus ONRIC b0240 (FERM BP-10065), and compositions containing the bacteria, the compositions being capable of stimulating mucosal immunity, and more specifically, the compositions in the form of foods or beverages or pharmaceutical products. The lactic acid bacteria and compositions containing the bacteria are capable of providing excellent mucosal immunostimulation effects and are useful for reinforcing the host defense system.Type: GrantFiled: August 18, 2004Date of Patent: November 30, 2010Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Satoko Yamahira, Masamichi Toba, Hiroshi Okamatsu
-
Patent number: 7838276Abstract: Carbohydrate utilization-related and multidrug transporter nucleic acids and polypeptides, and fragments and variants thereof, are disclosed in the current invention. In addition, carbohydrate utilization-related and multidrug transporter fusion proteins, antigenic peptides, and anti-carbohydrate utilization-related and anti-multidrug transporter antibodies are encompassed. The invention also provides vectors containing a nucleic acid of the invention and cells into which the vector has been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.Type: GrantFiled: October 22, 2008Date of Patent: November 23, 2010Assignee: North Carolina State UniversityInventors: Todd R. Klaenhammer, Eric R. Altermann, Rodolphe Barrangou, W. Michael Russell, Tri Duong
-
Patent number: 7837989Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.Type: GrantFiled: October 19, 2007Date of Patent: November 23, 2010Assignee: Mead Johnson Nutrition CompanyInventors: Udo Herz, Nicole Bluemer, Harald Renz, Holger Garn
-
Publication number: 20100291051Abstract: The present invention provides an agent for inhibition of alcoholic hepatopathy comprising cells of a strain belonging to Lactobacillus brevis, or treated product thereof as an active ingredient. The agent for inhibition of alcoholic hepatopathy of the present invention is safe for living body and can be used as a component in foods and beverages.Type: ApplicationFiled: January 14, 2009Publication date: November 18, 2010Applicant: SAPPORO BREWERIES LIMITEDInventors: Syuichi Segawa, Yoshihisa Wakita
-
Patent number: 7829079Abstract: The present invention provides methods and compositions for administration of Lactobacillus iners alone or together with at least one other probiotic organism such as Bifordobacterium, or another Lactobacillus for reduction of the risk of urogenital infection and concomitant restoration and/or maintenance of a healthy urogenital flora. A method of treatment of vaginal infections is also contemplated.Type: GrantFiled: March 28, 2003Date of Patent: November 9, 2010Assignee: Christian Hansen A/SInventors: Gregor Reid, Jeremy Burton
-
Patent number: 7829324Abstract: The present invention relates to a method for the microbiological isomerization of alpha-hydroxycarboxylic acids using an alpha-hydroxycarboxylic acid racemase, the enzymes used for this method and microorganisms which express a suitable racemase activity, a screening method for microorganisms with alpha-hydroxycarboxylic acid racemase activity, the nucleic acid sequences encoding this enzyme, expression vectors, recombinant microorganisms which express this racemase, and methods for the production or isolation of a protein with alpha-hydroxycarboxylic acid racemase activity.Type: GrantFiled: June 17, 2004Date of Patent: November 9, 2010Assignee: BASF SEInventors: Silvia Glück, Barbara Schnell, Monika Pirker, Kurt Faber
-
Publication number: 20100278794Abstract: An agent for promoting the secretion of adiponectin and/or suppressing decrease of adiponectin, a food or beverage for promoting the secretion of adiponectin and/or suppressing decrease of adiponectin, and a feed, each of which comprises a culture supernatant of Lactobacillus gasseri SBT2055 (FERM BP-10953) as an active ingredient.Type: ApplicationFiled: October 28, 2008Publication date: November 4, 2010Applicant: SNOW BRAND MILK PRODUCTS CO., LTD.Inventors: Yukiko Kunieda, Yasuyuki Seto, Yukio Kadooka
-
Publication number: 20100278795Abstract: An object of the present invention is to provide a useful composition that contains a highly safe lactic acid bacterium or a component derived from this lactic acid bacterium. The present invention relates to a composition comprising at least one lactic acid bacterium selected from the group consisting of Lactobacillus delbrueckii subsp. lactis strain KR-037 (NITE BP-395), Lactobacillus delbrueckii subsp. lactis strain KLAB-4 (NITE BP-394), and variants thereof, or comprising a component derived from the lactic acid bacterium. The composition of the present invention is useful as a preparation that has an excellent antiallergic function and also has at least one other function selected from an anti-autoimmune disease function, a diabetes-improving function, a neutral fat-lowering function, and so forth.Type: ApplicationFiled: November 19, 2008Publication date: November 4, 2010Applicant: Kaneka CorporationInventors: Airo Tategaki, Toyoki Watanabe, Kazuya Hamada
-
Publication number: 20100273239Abstract: A Lactobacillus helveticus bacterium composition for treatment of atopic dermatitis in a human.Type: ApplicationFiled: June 26, 2008Publication date: October 28, 2010Inventor: Benedicte Flambard
-
Publication number: 20100266727Abstract: The invention relates to a storage stable composition and method of manufacture containing a biological material, oil and a biopolymer which has a water activity of less than 0.5. The biological material in the composition attains significant stability and resistance to temperature, humidity and oxygen degradation. Advantages from the invention include the ability to stabilise, further process, store and then release the probiotic bacteria at a later date and retain viability. In addition the composition and method is more practical for producing and marketing of biological materials including probiotic material as it is simple, has low energy requirements and the resulting product is easy to incorporate in formulations and foods.Type: ApplicationFiled: November 6, 2008Publication date: October 21, 2010Applicant: ENCOATE HOLDINGS LIMITEDInventors: Jayanthi Swaminathan, Trevor Anthony Jackson
-
Publication number: 20100266550Abstract: The present invention relates to a novel approach to prevent or treat mastitis both in humans and animals through the use of mammal milk-derived microorganisms obtained from healthy hosts of the homologous species; to those new probiotic microorganisms obtained from milk able to reduce infectious mastitis and the method of screening used for their obtaining; to the use of these probiotic bacteria for the prophylaxis or treatment against mastitis and other diseases; and finally, to compositions comprising these compounds.Type: ApplicationFiled: June 2, 2008Publication date: October 21, 2010Applicant: PULEVA BIOTECH, S.A.Inventors: Rocio Martín Jiménez, Monica Olivares Martín, Esther Antonia Jiménez Quintana, Maria Luisa Marín Martínez, Saleta Sierra Ávila, Antonio Maldonado Barragán, Virginia Martín Merino, Francesc Blanch Martell, Celina Torre Lloveras, Federico Villoslada, Reebeca Arroyo Rodríguez, Julio Boza Puerta, Jesús Jiménez López, Leónides Fernández Álvarez, Odón Julían Sobrino Abuja, Jordi Xaus Pei, Juan Miguel Rodríguez Gómez, Susana Delgado Palacio
-
Publication number: 20100254948Abstract: This invention relates to a process for the production of gamma-aminobutyric acid (GABA) from Lactococcus lactis ssp. DSM 19464 and from Lactobacillus plantarum DSM 19463 or from their associations on must. In particular, this invention contemplates the selection and use of Lactococcus lactis ssp. DSM 19464 and of Lactobacillus plantarum DSM 19463 or their associations on must whose composition has been suitably optimized as to its composition, for the production of a preparation based on GABA, containing also vitamins, minerals, polyphenols and alive vital lactic bacteria for its potential use in the dermatological field.Type: ApplicationFiled: July 17, 2008Publication date: October 7, 2010Applicant: Giuliani S.p.AInventors: Giammaria Giuliani, Anna Benedusi, Raffaella Di Cagno, Carlo Giuseppe Rizzello, Maria De Angelis, Francesco Mazzacane, Marco Gobbetti
-
Publication number: 20100247575Abstract: The present invention provides Lactobacillus bacteria which enhance the functional of Peyer's patch and promote IgA production and which have a characteristics of localizing on human intestine as well as an agent for promoting IgA production.Type: ApplicationFiled: June 19, 2009Publication date: September 30, 2010Applicant: Calpis Co., Ltd.Inventors: Satoshi HACHIMURA, Hiroki Kanzato, Shigeru Fujiwara
-
Patent number: 7799551Abstract: Ferulate esterase producing bacterial strains or functional mutants thereof and methods of using ferulate esterase producing bacterial strains as forage additives are disclosed.Type: GrantFiled: September 1, 2005Date of Patent: September 21, 2010Assignee: Pioneer Hi-Bred International, Inc.Inventors: Victor Nsereko, William Rutherford, Brenda Smiley, Annette Spielbauer
-
Patent number: 7795000Abstract: The present invention relates to a composition including a microbial component and a foaming component, wherein the composition can be used to prevent the proliferation, or otherwise competitively exclude the continued growth of, undesirable microbes. The present invention also includes a method of using this composition.Type: GrantFiled: September 22, 2005Date of Patent: September 14, 2010Assignee: Ecolab Inc.Inventors: Teresa C. Podtburg, Bruce Schmidt, Bruce Cords, Lawrence A. Grab, David A. Halsrud
-
Publication number: 20100227378Abstract: A process for concentrating microorganism-containing suspensions comprising (a) centrifuging a microorganism-containing suspension to provide a first microorganism-containing concentrate and a supernatant liquid; (b) filtering said first microorganism-containing concentrate, to provide a permeate and a second microorganism-containing concentrate.Type: ApplicationFiled: March 5, 2010Publication date: September 9, 2010Applicant: Danisco A/SInventors: Lars Wexoe Petersen, Eric Hohol, Steve E. von Dollen
-
Publication number: 20100216212Abstract: An anti-obesity agent containing, as an active ingredient, a microorganism which belongs to the species Lactobacillus reuteri and is capable of producing lipases having the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5 or amino acid sequences having deletion, substitution or addition of one or more amino acids in the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5. The anti-obesity agent enables a patient to take a normal meal yet preventing the absorption of a fat into the body which is the primary cause of obesity.Type: ApplicationFiled: July 25, 2006Publication date: August 26, 2010Applicant: SCHOOL CORP., AZABU VETERIN MED. EDUCA'L INSTITUInventors: Hidetoshi Morita, Toshio Masaoka, Takehito Suzuki
-
Publication number: 20100203026Abstract: The invention relates to the field of nutrition and medicine. Provided are compositions, bacterial strains and methods for inducing or enhancing satiety and satiation and for treating or preventing obesity, overweight and overweight related diseases.Type: ApplicationFiled: July 25, 2007Publication date: August 12, 2010Applicant: CAMPINA NEDERLAND HOLDING B.V.Inventors: Marta Zdzislawa Korczynska, Wouter Noordman, Arthur Constantijn Ouwehand
-
Publication number: 20100203025Abstract: The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body.Type: ApplicationFiled: May 14, 2007Publication date: August 12, 2010Applicant: BIONEER CORPORATIONInventors: Ji Hee Kang, Byeung Il You, Sung Il Yun, Han Oh Park
-
Publication number: 20100203581Abstract: For the purpose of forming a biofilm having amount and strength sufficient for the immobilization of a cell mass, the present invention provides a method for producing a biofilm, characterized in that it comprises co-culturing lactic acid bacteria belonging to Lactobacillus plantarum with yeast.Type: ApplicationFiled: July 29, 2008Publication date: August 12, 2010Applicant: Nihon University UniversityInventors: Yasushi Morinaga, Soichi Furukawa, Hirokazu Ogihara, Makari Yamasaki
-
Patent number: 7771982Abstract: The present invention relates to novel lactic acid bacterial micro-organisms that have been isolated and selected for their probiotic potential and their use for the preparation of petfood compositions intended to improve the health of pets, and to compositions containing the same.Type: GrantFiled: February 2, 2007Date of Patent: August 10, 2010Assignee: Nestec S.A.Inventors: Ralf Zink, Roberto Reniero, Florence Rochat, Christoph Cavadini, Thierry Der Weid, Eduardo Schiffrin, Jalil Benyacoub, Virginia Rousseau, Pablo Perez
-
Publication number: 20100196341Abstract: A novel Lactobacillus paracasei subsp. paracasei SG96, a bacteriostatic composition containing the same and use thereof, comprise a novel Lactobacillus paracasei subsp. paracasei SG96 strain, wherein said strain had been deposited in China General Microbiological Culture Collection Center, CGMCC, accession number: CGMCC 2697, characterized in that said strain can inhibit the growth of pathogenic bacteria such as Escherichia coli, Salmonella typhimurium and the like, and even has an effect of killing bacteria; and a bacteriostatic composition containing said Lactobacillus paracasei subsp. paracasei SG96 strain, characterized in that said composition can be used as an additive in animal drinking water, as an additive in animal feed, as an medical composition for animals and humans, as an additive in food products as an additive in beverages, and as a food product, beverage, and health food products, and the like.Type: ApplicationFiled: February 5, 2009Publication date: August 5, 2010Applicant: SYNGEN BIOTECH CO., LTD.Inventors: Yu-Shan WEI, Fang-Yun TAI
-
Patent number: 7767430Abstract: The present invention pertains to novel microorganisms of the genus Bifidobacterium, that are useful in preventing diarrhea brought about by pathogenic bacteria. In particular, the present invention relates to the use of said microorganisms for the preparation of an ingestable support and to a composition containing the same.Type: GrantFiled: June 30, 2005Date of Patent: August 3, 2010Assignee: Nestec S.A.Inventors: Jean-Richard Neeser, Roberto Reniero, Florence Rochat, Alain Servin
-
Publication number: 20100183574Abstract: TRFs useful for identifying strains of interest are provided. A method of identifying one or more strain that can be used as a direct-fed microbial is also provided. One or more strain identified by the method is additionally provided. A method is also provided for administering to an animal an effective amount of the one or more strain. Additionally provided is an isolated strain chosen from at least one of Lactobacillus acidophilus strain PlB c6 (NRRL B-50103), Lactobacillus salivarius strain o246e 33w (NRRL B-50102), Pediococcus acidilactici strain o246e 42 (NRRL B-50171), and Pediococcus acidilactici strain PlJ e3 (NRRL B-50101). An isolated strain having all of the identifying characteristics of one of the strains listed above is also provided. One or more strain can be administered as a direct-fed microbial to an animal. Methods of preparing a direct-fed microbial are also provided.Type: ApplicationFiled: January 12, 2010Publication date: July 22, 2010Applicants: DANISCO A/S, The Board of Trustees of the Univ. of Arkansas, acting for and on behalf of the Univ. of ArkansasInventors: Mari Ellen Davis, Joshua Rehberger, Charles Maxwell, Thomas Rehberger, Mike King
-
Publication number: 20100183768Abstract: A new method for making a composition comprising a particle containing cell culture (e.g. a lactic acid bacteria culture) suspended in oil, a lipid, a wax or a mixture of those, wherein the composition gives improved storage stability of the cell of interest.Type: ApplicationFiled: June 27, 2008Publication date: July 22, 2010Inventors: Karsten Baaner, Mette Winning, Peter Wagner
-
Patent number: 7759108Abstract: There are disclosed methods for producing fermented milk and whey that enable effective production in high yield of fermented milk and whey having high content of an ACEI peptide that is highly safe and applicable to pharmaceuticals, functional foods, health foods, and the like. The methods are: a method including the steps of mixing lactic acid bacteria and a starting material containing milk by stirring to prepare a mixed material, and fermenting the mixed material under stirring so that curd pieces and whey containing an angiotensin converting enzyme inhibitory peptide are generated, whereby fermented milk containing the curd pieces and the whey containing the angiotensin converting enzyme inhibitory peptide is produced; and a method including the steps of subjecting the resulting fermented milk to centrifugation and/or filter pressing to separate and recover whey.Type: GrantFiled: November 13, 2006Date of Patent: July 20, 2010Assignee: Calpis Co., Ltd.Inventors: Shuji Kitamura, Takashi Ueyama
-
Publication number: 20100178387Abstract: The present invention relates to a method for making cheese of the continental type or the cheddar type, especially reduced-fat or low-fat cheese.Type: ApplicationFiled: April 17, 2008Publication date: July 15, 2010Applicant: CHR. HANSEN A/SInventors: Marie-Claude Bezenger, Ilka Eppert, Niels Kristian Soerensen, Erik Hoeier, Anne-Gaelle Le Tual, Mikkel Laust Broe
-
Publication number: 20100173371Abstract: The present invention relates to a medium composition comprising fermented Korean hot pepper paste, undiluted solution of brewed soy sauce or acid hydrolyzed soy sauce, and a method for producing gamma-aminobutyric acid (GABA) using the medium. More precisely, the present invention relates to a medium composition for culturing lactobacillus having GAD activity, the composition comprising fermented hot pepper paste, brewed soy sauce or acid hydrolyzed soy sauce, and a method for producing a high concentration of gamma-aminobutyric acid from the medium additionally added with glutamic acid or glutamate. The present invention provides a method of producing a high concentration of gamma-aminobutyric acid using the above medium with low production costs. Since the by-products of pastes are used as medium compositions, this medium itself can be added to other pastes or foods to produce functional foods containing gamma-aminobutyric acid.Type: ApplicationFiled: December 22, 2006Publication date: July 8, 2010Applicant: CJ CHEILJEDANG CORPORATIONInventors: Myoung-hee Jeon, Seung-jin Lee, Byoung-koo Kwon, Yeong-il Chang, Hee-kyoung Park, Jun-bong Choi
-
Patent number: 7744868Abstract: One embodiment of the present invention is directed to the use of a novel competitive exclusion bacterial composition to prevent or reduce Salmonella or Campylobacter colonization in poultry.Type: GrantFiled: November 22, 2004Date of Patent: June 29, 2010Assignee: University of Georgia Research FoundationInventors: Michael P. Doyle, Guodong Zhang, Li Ma
-
Publication number: 20100158882Abstract: The present invention relates to immuno modulating probiotic lactic acid bacteria, to methods wherein the bacteria are used to reduce allergy, and to food products wherein the bacteria may be in incorporated to reduce allergy upon consumption of the product. Preferred probiotic lactic acid bacteria stimulate the Th1 and/or Th3 responses and/or represses Th2 responses as may be determined by the cytokine profiles that are induced in human peripheral blood mononuclear cells upon coincubation with the lactic acid bacteria.Type: ApplicationFiled: December 21, 2007Publication date: June 24, 2010Inventors: Peter Frederik Zuurendonk, Michiel Kleerebezem, Johannes Snel, Maria Marco, Hubertus Franciscus Jozef Savelkoul
-
Patent number: 7741109Abstract: An applicator for applying a liquid carrier having live bacteria suspended therein, which are in a dormant state, to a target host comprising a pump having inlet and discharge sides, with the inlet side of the pump being in fluid communication with the liquid carrier. A first fluid conduit extends from the discharge side of the pump to an air induction nozzle which is in communication with a source of air under pressure. A flow control is imposed in the first conduit for adjusting the amount of liquid carrier passing therethrough. The pump and the air supply for the air induction nozzle are operatively connected to a power supply. The pump, when activated, causes the liquid carrier to be pumped to the air induction nozzle wherein the liquid carrier is mixed with air to create small droplets thereof for spraying onto the target host.Type: GrantFiled: June 2, 2004Date of Patent: June 22, 2010Inventor: James B. Watson
-
Publication number: 20100151026Abstract: The invention provides a naturally occurring strain of Lactobacillus crispatus with advantageous characteristics. The strain colonizes mucosal surfaces, particularly vaginal surfaces. The strain is also capable of rapid growth in a number of conditions and is highly viable after desiccation. Moreover, the strain is capable of preventing and reducing pathogenic infection of vaginal mucosa.Type: ApplicationFiled: December 9, 2009Publication date: June 17, 2010Applicant: Osel, Inc.Inventors: Yang Liu, Rosa R. Yu, Andrew Cheng, Qing Xia, Qiang Xu